News | July 14, 2009

ACRIN's PET Core Laboratory Provides QA Tool for Research

Deputy Co-chair and Medical Director, PET Core Laboratory, ACRIN, Barry A. Siegel, M.D.

July 14, 2009 - ACRIN has developed a qualification procedure for Positron Emission Tomography (PET) scanners at participating institutions designed to check the basic system calibrations and to verify that the clinical image quality is adequate for semiquantitative analysis of PET data, reported a paper published online in the Journal of Nuclear Medicine, Vol. 50, No. 7, on June 12, 2009. 
The American College of Radiology (ACR) Image Metrix works closely with the American College of Radiology Imaging Network (ACRIN) to conduct PET trials. The PET core laboratory of ACRIN qualifies sites to participate in multicenter research trials by reviewing the quantitative data of PET scans and qualitatively reviewing clinical PET images from each site.

Of 101 detailed scanner applications, 12 percent failed because of incorrect standardized uptake value (SUV) or normalization calibrations. Minimizing errors in SUV measurement is critical to achieving accurate quantification in clinical trials. ACRIN’s PET core laboratory shows that many sites are unable to maintain accurate SUV calibrations without additional training or supervision.

“Information obtained from PET imaging has increasingly demonstrated its promising role as a non-invasive biomarker for assessing disease status,” stated lead author, Joshua Scheuermann, MS, clinical physicist at the University of Pennsylvania. “The goal of the PET qualification program is to ensure we are obtaining reliable quantitative and qualitative data across all of the centers participating in PET clinical research.” 
  
“The emerging role of PET imaging endpoints as in vivo biomarkers requires imaging studies to produce reliable quantitative, semi-quantitative and qualitative results that can be used to assess disease status. Ensuring such consistency in multi-center clinical trials that involve imaging is problematic. The problem stems from the fact that the data acquisition and reconstruction are performed in many different settings and often with different types of instrumentation.  As described in our most recent peer reviewed publication, ACRIN has managed to develop a robust system to streamline data collection, data management and processing.  Such system is paving the way for a better integration of molecular imaging in drug discovery processes,” stated Deputy Co-chair and Medical Director, PET Core Laboratory, ACRIN, Barry A. Siegel, M.D. 
 
“The results from this highlight the importance of a central review of a site’s data and images before data from a PET scanner can be used,” stated ACR Image Metrix General Manager, Michael Morales. “The PET core laboratory is a key component of our research center providing accurate, reliable research results.”

For more information: www.acr-imagemetrix.net and www.acrin.org

Related Content

FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Overlay Init